Dublin, Ireland, March 14, 2025 – IPS-Integrated Project Services, a global leader in delivering integrated design, engineering, procurement, construction management, and validation (EPCMV) services for the pharmaceutical and biotechnology industries, is pleased to announce the appointment of Karl Page as Senior Director of Ireland.
With over 20 years of leadership experience in the technology and life sciences sectors, Karl has successfully led complex EPCM projects across EMEA. His expertise in project execution, operational excellence, and strategic growth positions him to lead IPS’ expansion in Ireland and drive further momentum across the region.
“Karl’s appointment marks a pivotal moment for IPS as we scale our operations in response to increasing demand,” said Peter Higgins, EMEA Managing Director at IPS. “Ireland is at the heart of the global pharmaceutical supply chain, and we are committed to delivering world-class solutions that enable our clients to bring life-changing therapies to market.”
IPS currently operates two offices in Ireland—Cork and Dublin—and due to significant growth and increased project demand, IPS is relocating to a larger office space in Dublin in April 2025. This expansion aligns with IPS’ recent major project win—being appointed as the EPCM contractor for GE Healthcare’s new €130 million manufacturing facility in Cork. This project is part of Ireland’s continued investment in pharmaceutical infrastructure, reinforcing the country’s status as a life sciences powerhouse. https://bit.ly/GE-Healthcare-Cork
Karl Page shared his enthusiasm for joining IPS: "IPS has built a strong reputation for delivering complex, high-value projects for the world’s leading pharmaceutical and biotech companies. As Ireland continues to attract major investments in manufacturing, IPS is uniquely positioned to support this demand. I look forward to working with our exceptional teams in Cork and Dublin to strengthen our client partnerships and advance our impact across the region."
IPS expansion in Ireland is part of a broader EMEA growth strategy, with the company now operating across nine locations and a team of over 500 professionals and growing. This momentum reflects the company’s continued investment in global talent and its commitment to building a healthier, more sustainable world through innovation in pharmaceutical and biotechnology facility design.
